Business Wire | Dec 16, 2021 08:30AM EST

ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index

Dec. 16, 2021

ATLANTA & NEW YORK--(BUSINESS WIRE)--Dec. 16, 2021--Intercontinental Exchange, Inc. (NYSE: ICE), a leading global provider of data, technology and market infrastructure, today announced the annual reconstitution of the ICE Biotechnology Index (ICEBIO), which is effective before the open of trading on Monday, December 20, 2021.

The ICE Biotechnology Index tracks the performance of qualifying U.S. listed biotechnology companies classified within the Biotechnology Sub-Industry Group of the ICE Uniform Sector Classification schema, which is a multi-asset class industry classification taxonomy developed by ICE. The index includes companies that are engaged in the research and development of therapeutic treatments but are not focused on the commercialization and mass production of pharmaceutical drugs. The index also includes companies that are engaged in the production of tools or systems that enable biotechnology processes.

"This annual reconstitution ensures that the index maintains its representation of the broader biotechnology industry," said Aram Flores, Head of Index and Analytics at ICE. "By including companies meeting a minimum threshold of market capitalization and liquidity from multiple U.S. exchanges, the index provides a better gauge of the biotechnology industry and helps improve the investability for users benchmarking to the index."

The following companies will be added to and removed from the index in the December 2021 annual reconstitution:

Ticker Name Action

ABCL AbCellera Biologics, Inc. Addition

ABCM Abcam PLC Sponsored ADR Addition

ABOS Acumen Pharmaceuticals, Inc. Addition

ABSI Absci Corporation Addition

ACET Adicet Bio Inc Addition

ACHL Achilles Therapeutics PLC Sponsored ADR Addition

ACRS Aclaris Therapeutics, Inc. Addition

ADMA ADMA Biologics, Inc. Addition

AKUS Akouos, Inc. Addition

AKYA Akoya Biosciences Inc Addition

ALGS Aligos Therapeutics, Inc. Addition

ALPN Alpine Immune Sciences, Inc. Addition

ALVR AlloVir Inc Addition

AMPE Ampio Pharmaceuticals, Inc. Addition

ANVS Annovis Bio Inc Addition

ATAI ATAI Life Sciences N.V. Addition

ATHA Athira Pharma, Inc. Addition

AUPH Aurinia Pharmaceuticals Inc. Addition

AUTL Autolus Therapeutics Plc Sponsored ADR Addition

AVIR Atea Pharmaceuticals, Inc. Addition

AVTE Aerovate Therapeutics, Inc. Addition

AVXL Anavex Life Sciences Corp. Addition

BCAB BioAtla, Inc. Addition

BCYC Bicycle Therapeutics Plc Sponsored ADR Addition

BLU BELLUS Health Inc. Addition

BMEA Biomea Fusion Inc Addition

BNR Burning Rock Biotech Ltd. Sponsored ADR Class A Addition

BOLT Bolt Biotherapeutics, Inc. Addition

BTX Brooklyn ImmunoTherapeutics, Inc. Addition

CADL Candel Therapeutics, Inc. Addition

CCCC C4 Therapeutics, Inc. Addition

CDAK Codiak BioSciences, Inc. Addition

CGEM Cullinan Oncology, Inc. Addition

CLSD Clearside Biomedical, Inc. Addition

CMPS COMPASS Pathways Plc Sponsored ADR Addition

CMRX Chimerix, Inc. Addition

CNTA Centessa Pharmaceuticals PLC ADR Addition

CNTB Connect Biopharma Holdings Ltd. Sponsored ADR Addition

CRBU Caribou Biosciences, Inc. Addition

CRIS Curis, Inc. Addition

CTKB Cytek Biosciences, Inc. Addition

CVAC CureVac N.V. Addition

CYBN Cybin, Inc. Addition

CYT Cyteir Therapeutics, Inc. Addition

DAWN Day One Biopharmaceuticals, Inc. Addition

DBTX Decibel Therapeutics, Inc. Addition

DBVT DBV Technologies SA Sponsored ADR Addition

DNAY Codex DNA, Inc. Addition

DSGN Design Therapeutics, Inc. Addition

DYN Dyne Therapeutics Inc Addition

ERAS Erasca, Inc. Addition

ETNB 89bio Inc Addition

EVLO Evelo Biosciences, Inc. Addition

EWTX Edgewise Therapeutics, Inc. Addition

FDMT 4D Molecular Therapeutics, Inc. Addition

GLUE Monte Rosa Therapeutics, Inc. Addition

GRCL Gracell Biotechnologies Inc. Sponsored ADR Class A Addition

GRPH Graphite Bio, Inc. Addition

GRTS Gritstone bio, Inc. Addition

GTH Genetron Holdings Ltd Sponsored ADR Addition

HBIO Harvard Bioscience, Inc. Addition

HOWL Werewolf Therapeutics, Inc. Addition

HUMA Humacyte, Inc. Addition

ICVX Icosavax, Inc. Addition

IKNA Ikena Oncology, Inc. Addition

IMGO Imago BioSciences, Inc. Addition

IMMP Immutep Ltd Sponsored ADR Addition

IMPL Impel NeuroPharma, Inc. Addition

IMRX Immuneering Corp. Class A Addition

INBX Inhibrx Inc Addition

INFI Infinity Pharmaceuticals, Inc. Addition

IPHA Innate Pharma SA Sponsored ADR Addition

IPSC Century Therapeutics, Inc. Addition

JANX Janux Therapeutics, Inc. Addition

KMDA Kamada Ltd Addition

KMPH KemPharm, Inc. Addition

KNTE Kinnate Biopharma, Inc. Addition

KRON Kronos Bio Inc Addition

KYMR Kymera Therapeutics, Inc. Addition

LABP Landos Biopharma, Inc. Addition

LCTX Lineage Cell Therapeutics, Inc. Addition

LPTX Leap Therapeutics, Inc. Addition

LYEL Lyell Immunopharma, Inc. Addition

MBIO Mustang Bio, Inc. Addition

MIRM Mirum Pharmaceuticals, Inc. Addition

MORF Morphic Holding, Inc. Addition

MREO Mereo BioPharma Group plc Sponsored ADR Addition

MRUS Merus N.V. Addition

MRVI Maravai LifeSciences Holdings Inc Class A Addition

MTEM Molecular Templates, Inc. Addition

MTNB Matinas BioPharma Holdings, Inc. Addition

MXCT MaxCyte, Inc. Addition

NAUT Nautilus Biotechnolgy, Inc. Addition

NRXP NRX Pharmaceuticals, Inc. Addition

NUVB Nuvation Bio Inc Class A Addition

NUVL Nuvalent, Inc. Class A Addition

OBSV ObsEva SA Addition

OCX Oncocyte Corporation Addition

OLK Olink Holding AB Sponsored ADR Addition

OLMA Olema Pharmaceuticals, Inc. Addition

OMGA Omega Therapeutics, Inc. Addition

OMIC Singular Genomics Systems, Inc. Addition

ONCR Oncorus, Inc. Addition

OYST Oyster Point Pharma Inc Addition

PCVX Vaxcyte, Inc. Addition

PHAT Phathom Pharmaceuticals, Inc. Addition

PMVP PMV Pharmaceuticals, Inc. Addition

PRAX Praxis Precision Medicines, Inc. Addition

PRLD Prelude Therapeutics, Inc. Addition

PRQR ProQR Therapeutics N.V. Addition

RAIN Rain Therapeutics Inc Addition

RANI Rani Therapeutics Holdings, Inc. Class A Addition

RLYB Rallybio Corporation Addition

ROIV Roivant Sciences Ltd. Addition

RXDX Prometheus Biosciences, Inc Addition

RXRX Recursion Pharmaceuticals, Inc Class A Addition

SANA Sana Biotechnology, Inc. Addition

SBTX Silverback Therapeutics, Inc. Addition

SEER Seer, Inc. Class A Addition

SESN Sesen Bio, Inc. Addition

SLDB Solid Biosciences Inc. Addition

SMMT Summit Therapeutics Inc Addition

SNSE Sensei Biotherapeutics, Inc. Addition

SQZ SQZ Biotechnologies Company Addition

STTK Shattuck Labs, Inc. Addition

STVN Stevanato Group SpA Addition

SYNH Syneos Health, Inc. Class A Addition

TALS Talaris Therapeutics, Inc. Addition

TERN Terns Pharmaceuticals, Inc. Addition

TIL Instil Bio, Inc. Addition

TKNO Alpha Teknova, Inc. Addition

TNYA Tenaya Therapeutics, Inc. Addition

TSHA Taysha Gene Therapies, Inc. Addition

VERV Verve Therapeutics, Inc. Addition

VIRX Viracta Therapeutics, Inc. Addition

VOR Vor Biopharma, Inc. Addition

VRCA Verrica Pharmaceuticals Inc. Addition

AMRS Amyris, Inc. Deletion

APRE Aprea Therapeutics, Inc. Deletion

ARDX Ardelyx, Inc. Deletion

ASMB Assembly Biosciences, Inc. Deletion

BCEL Atreca, Inc. Class A Deletion

CALA Calithera Biosciences, Inc. Deletion

CERS Cerus Corporation Deletion

CNCE Concert Pharmaceuticals, Inc. Deletion

EGRX Eagle Pharmaceuticals, Inc. Deletion

ESPR Esperion Therapeutics, Inc. Deletion

GH Guardant Health, Inc. Deletion

INZY Inozyme Pharma, Inc. Deletion

KALA Kala Pharmaceuticals, Inc. Deletion

KLDO Kaleido Biosciences, Inc. Deletion

MNOV MediciNova, Inc. Deletion

MOR MorphoSys AG Sponsored ADR Deletion

NCNA NuCana plc Sponsored ADR Deletion

ODT Odonate Therapeutics, Inc. Deletion

OMER Omeros Corporation Deletion

SIGA SIGA Technologies Inc Deletion

SUPN Supernus Pharmaceuticals, Inc. Deletion

TLSA Tiziana Life Sciences Ltd. Deletion

UBX Unity Biotechnology, Inc. Deletion

VRNA Verona Pharma plc Sponsored ADR Deletion

VYGR Voyager Therapeutics, Inc. Deletion

XBIT XBiotech, Inc. Deletion

ICE's global family of indices serve as the performance benchmark for more than $1 trillion in assets managed by investors around the globe. For more information about ICE's Indices, please visit: https://www.ice.com/market-data/indices.

About Intercontinental Exchange

Intercontinental Exchange, Inc. (NYSE: ICE) is a Fortune 500 company that designs, builds and operates digital networks to connect people to opportunity. We provide financial technology and data services across major asset classes that offer our customers access to mission-critical workflow tools that increase transparency and operational efficiencies. We operate exchanges, including the New York Stock Exchange, and clearing houses that help people invest, raise capital and manage risk across multiple asset classes. Our comprehensive fixed income data services and execution capabilities provide information, analytics and platforms that help our customers capitalize on opportunities and operate more efficiently. At ICE Mortgage Technology, we are transforming and digitizing the U.S. residential mortgage process, from consumer engagement through loan registration. Together, we transform, streamline and automate industries to connect our customers to opportunity.

Trademarks of ICE and/or its affiliates include Intercontinental Exchange, ICE, ICE block design, NYSE and New York Stock Exchange. Information regarding additional trademarks and intellectual property rights of Intercontinental Exchange, Inc. and/or its affiliates is located here. Key Information Documents for certain products covered by the EU Packaged Retail and Insurance-based Investment Products Regulation can be accessed on the relevant exchange website under the heading "Key Information Documents (KIDS)."

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 -- Statements in this press release regarding ICE's business that are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see ICE's Securities and Exchange Commission (SEC) filings, including, but not limited to, the risk factors in ICE's Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC on February 4, 2021.

SOURCE: Intercontinental Exchange

ICE-CORP

View source version on businesswire.com: https://www.businesswire.com/news/home/20211216005424/en/

CONTACT: ICE Media Contact: Damon Leavell damon.leavell@ice.com (212) 323-8587

CONTACT: media@ice.com

CONTACT: ICE Investor Contact: Mary Caroline O'Neal marycaroline.oneal@ice.com (770) 738-2151

CONTACT: investors@ice.com